Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines

Scriba, Thomas J.; Kaufmann, Stefan H. E.; Lambert, Paul Henri; Sanicas, Melvin; Martín, Carlos; Neyrolles, Olivier

doi:10.1093/infdis/jiw228

Cited by 52 publications

(43 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Research with recombinant BCG strains continues (reviewed in reference 12). Gengenbacher et al report that the inflammasome activation and autophagy induced by VPM1002 can be further enhanced through the deletion of nuoG (BCG Δ ureC :: hly Δ nuoG ) (13).…”

Section: Recombinant Bcg Vaccinesmentioning

confidence: 99%

Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine

Fletcher

2016

mBio

View full text Add to dashboard Cite

Mycobacterium bovis BCG is the only available vaccine for protection against tuberculosis (TB). While BCG protects children from severe disease, it has little impact on pulmonary disease in adults. A recombinant BCG vaccine BCG ΔureC::hly (strain VPM1002) is in advanced clinical trials and shows promise for improved vaccine safety but little change in efficacy in animal models. A second-generation recombinant BCG vaccine with an additional deletion of the nuoG gene (BCG ΔureC::hly ΔnuoG) shows improved efficacy in a mouse model compared to that of VPM1002. BCG was first used in humans in 1921 and, like Sleeping Beauty pricked by the spinning wheel, we have slept for 100 years, showing a reluctance to invest in clinical development or in biomanufacturing capacity for TB vaccines. The advance of recombinant BCGs should awaken us from our sleep and call us to invest in new-generation TB vaccines and to protect the biomanufacture of our current BCG vaccine.

show abstract

Section: Recombinant Bcg Vaccinesmentioning

confidence: 99%

Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine

Fletcher

2016

mBio

View full text Add to dashboard Cite

show abstract

“…These vaccines are expected to safely induce more specific and longer-lasting immune responses in humans that can provide protection against TB [38]. This is the rationale that has been followed in the development of the liveattenuated MTBVAC.…”

Section: The Current Clinical Tb Vaccine Pipelinementioning

confidence: 99%

Section: Expert Commentarymentioning

confidence: 99%

“…polio, measles, yellow fever) [38]. Although debatable in clinic, live BCG is typically the most protective vaccine against M. tuberculosis in experimental animal models [38], which makes one consider that human vaccination with live-attenuated M. tuberculosis (e.g. MTBVAC) would induce specific long-term immune responses against certain T cell epitopes that are present in M. tuberculosis and absent in BCG and which may be important for protection [38,83].…”

Section: Expert Commentarymentioning

confidence: 99%

“…Although debatable in clinic, live BCG is typically the most protective vaccine against M. tuberculosis in experimental animal models [38], which makes one consider that human vaccination with live-attenuated M. tuberculosis (e.g. MTBVAC) would induce specific long-term immune responses against certain T cell epitopes that are present in M. tuberculosis and absent in BCG and which may be important for protection [38,83]. Moreover, neonatal vaccination with live-attenuated M. tuberculosis vaccines could represent by far the most effective strategy for conferring high-quality protective immunity against TB, as healthy newborns represent the most sensitive and immunologically naïve population without preexisting mycobacterial immunity, which in older age groups can lead to potential masking and blocking effects to vaccination [18,87].…”

Section: Expert Commentarymentioning

confidence: 99%

See 2 more Smart Citations

MTBVAC from discovery to clinical trials in tuberculosis-endemic countries

Marinova

Gonzalo-Asensio

Aguilo

et al. 2017

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

Introduction: BCG remains the only vaccine against tuberculosis (TB) in use today and despite its impressive global coverage, the nature of BCG protection against the pulmonary forms of TB remains subject to ongoing debate. Because of the limitations of BCG, novel TB vaccine candidates have been developed and several have reached the clinical pipeline. One of these candidates is MTBVAC, the first and only TB vaccine in the clinical pipeline to date based on live-attenuated Mycobacterium tuberculosis that has successfully entered clinical evaluation, a historic milestone in human vaccinology. Areas covered: This review describes development of MTBVAC from discovery to clinical development in high burden TB-endemic countries. The preclinical experiments where MTBVAC has shown to confer improved safety and efficacy over BCG are presented and the clinical development plans for MTBVAC are revealed. The search of all supportive literature in this manuscript was carried out via Pubmed. Expert commentary: Small experimental medicine trials in humans and preclinical efficacy studies with a strong immunological component mimicking clinical trial design are considered essential by the scientific community to help identify reliable vaccine-specific correlates of protection in order to support and accelerate community-wide efficacy trials of new TB vaccines. ARTICLE HISTORY

show abstract

Expression of ESAT‐6 antigen from Mycobacterium tuberculosis in broccoli: An edible plant

Saba

Sameeullah

Asghar

et al. 2020

Biotech and App Biochem

View full text Add to dashboard Cite

Tuberculosis (TB) is one of the major infectious diseases caused by Mycobacterium tuberculosis. The development of an effective and economical vaccine for controlling TB is essential especially for developing countries. Edible plants can serve as biofactories to produce vaccine antigens. In this study, 6 kDa early secretory antigenic target (ESAT‐6) of M. tuberculosis was expressed in Brassica oleracea var. italica via Agrobacterium‐mediated transformation to facilitate oral delivery of antigen. ESAT‐6 gene was cloned using Gateway® cloning strategy. Transformation and presence of transgene was confirmed through PCR. Expression level of transgene was calculated via quantitative real‐time PCR (qRT‐PCR) and the maximum integrated transgene number was two. Maximum amount of total soluble fraction of ESAT‐6 was evaluated by immunoblotting, estimated to accumulate up to 0.5% of total soluble protein. The recombinant ESAT‐6 protein was further purified and detected using silver staining and Western blotting. ESAT‐6 protein induced humoral immune response in mice immunized orally and subcutaneously. The expression of M. tuberculosis antigen in edible plants could aid in the development of cost‐effective and oral delivery of an antigen‐based subunit vaccine against TB. To the best our knowledge, it is the first report of expression of a vaccine antigen in broccoli.

show abstract

Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines

Cited by 52 publications

References 49 publications

Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine

Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine

MTBVAC from discovery to clinical trials in tuberculosis-endemic countries

Expression of ESAT‐6 antigen from Mycobacterium tuberculosis in broccoli: An edible plant

Contact Info

Product

Resources

About